S'abonner

Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis - 27/04/14

Doi : 10.1016/j.jaci.2013.08.026 
Laura Van Gerven, MD a, b, Yeranddy A. Alpizar c, Mira M. Wouters, PhD d, Valérie Hox, MD, PhD a, b, Esther Hauben, MD, PhD e, f, Mark Jorissen, MD, PhD a, Guy Boeckxstaens, MD, PhD d, Karel Talavera, PhD c, Peter W. Hellings, MD, PhD a, b,
a Clinical Division of Otorhinolaryngology, Head & Neck Surgery, University Hospitals Leuven, Leuven, Belgium 
f Clinical Division of Pathology, University Hospitals Leuven, Leuven, Belgium 
b Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium 
c Laboratory for Ion Channel Research, Department of Molecular Cell Biology, KU Leuven, Leuven, Belgium 
d Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium 
e Laboratory of Translational Cell and Tissue Research, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium 

Corresponding author: Peter W. Hellings, MD, PhD, University Hospitals Leuven, Clinical Division of Otorhinolaryngology, Head & Neck Surgery, Kapucijnenvoer 33, 3000 Leuven, Belgium.

Abstract

Background

Idiopathic rhinitis (IR) is a prevalent condition for which capsaicin nasal spray is the most effective treatment. However, the mechanisms underlying IR and the therapeutic action of capsaicin remain unknown.

Objective

We sought to investigate the molecular and cellular bases of IR and the therapeutic action of capsaicin.

Methods

Fourteen patients with IR and 12 healthy control subjects (HCs) were treated with intranasal capsaicin. The therapeutic effect was assessed in patients with IR by using visual analog scale and therapeutic response evaluation scores, and nasal hyperreactivity was evaluated by means of cold dry air provocation. Nasal samples served to measure the levels of neuromediators and expression of chemosensory cation channels, protein gene product 9.5 (PGP 9.5), and the mast cell marker c-kit. The effects of capsaicin were also tested in vitro on human nasal epithelial cells and mast cells.

Results

Patients with IR had higher baseline transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) expression in the nasal mucosa and higher concentrations of substance P (SP) in nasal secretions than HCs. Symptomatic relief was observed in 11 of 14 patients with IR after capsaicin treatment. Expression of TRPV1; transient receptor potential cation channel subfamily M, receptor 8 (TRPM8); and PGP 9.5 was only reduced in patients with IR after capsaicin treatment. Capsaicin did not alter c-KIT expression or nasal epithelial morphology in patients with IR and HCs nor did it induce apoptosis or necrosis in cultured human nasal epithelial cells and mast cells.

Conclusion

IR features an overexpression of TRPV1 in the nasal mucosa and increased SP levels in nasal secretions. Capsaicin exerts its therapeutic action by ablating the TRPV1-SP nociceptive signaling pathway in the nasal mucosa.

Le texte complet de cet article est disponible en PDF.

Key words : Capsaicin treatment, idiopathic rhinitis, nasal hyperreactivity, TRPV1, afferent nerves, TRPV1-SP signaling pathway

Abbreviations used : CDA, CGRP, FITC, HC, IR, NANIR, NEC, NHR, NKA, PGP 9.5, PI, PNIF, SP, SPT, TRE, TRPA1, TRPM8, TRPV1, TUNEL, VAS


Plan


 L.V.G. is supported by a grant of the Agency for Innovation by Science and Technology in Flanders, Belgium (IWT). P.W.H. is a recipient of a senior researcher fellowship from the Fund for Scientific Research Flanders, Belgium (FWO). M.M.W. is a postdoctoral researcher of the Fund for Scientific Research (FWO), Flanders, Belgium. G.B. is supported by a governmental grant (Odysseus program, G.0905.07, FWO). This work was also supported by grants from the Belgian Federal Government (IUAP P6/28), the FWO (G.0565.07 and G.0686.09), IWT (TBM project 130260), and the Research Council of the KU Leuven (GOA 2009/07 and 14/011, EF/95/010 and PFV/10/006).
 Disclosure of potential conflict of interest: L. Van Gerven has been supported by one or more grants from IWT. P. W. Hellings is a Board member for the European Academy of Allergy and Clinical Immunology, the European Respiratory Society, and EAFPS; has received one or more grants from or has one or more grants pending with GlaxoSmithKline and Stallergenes; and has received one or more payments for lecturing from or is on the speakers' bureau for GlaxoSmithKline, MSD, and Stallergenes. The rest of the authors declare that they have no relevant conflicts of interest.


© 2013  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 133 - N° 5

P. 1332 - mai 2014 Retour au numéro
Article précédent Article précédent
  • Early-life weight gain, prematurity, and asthma development
  • Leonard B. Bacharier
| Article suivant Article suivant
  • Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure
  • Robert L. Jacobs, Nathan Harper, Weijing He, Charles P. Andrews, Cynthia G. Rather, Daniel A. Ramirez, Sunil K. Ahuja

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.